Maternal serum analyte levels after first-trimester multifetal pregnancy reduction

Area of Science:

• Maternal-Fetal Medicine
• Reproductive Endocrinology
• Clinical Chemistry

Background:

• Multifetal pregnancy reduction is performed to improve pregnancy outcomes.
• Maternal serum analytes are used for prenatal screening of fetal abnormalities.
• The impact of multifetal pregnancy reduction on these screening markers is not fully understood.

Purpose of the Study:

• To evaluate the effect of first-trimester multifetal pregnancy reduction on maternal serum levels of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.
• To assess the utility of these analytes for prenatal screening after multifetal pregnancy reduction.

Main Methods:

• Blood samples collected from 10 women post-first-trimester multifetal pregnancy reduction (15.09–20.9 weeks' gestation).
• Assayed for alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.
• Analyte concentrations interpreted within a maternal serum screening program.

Main Results:

• Significantly elevated alpha-fetoprotein levels observed in all samples.
• Human chorionic gonadotropin and unconjugated estriol levels correlated with the number of continuing gestations.
• No significant alteration in human chorionic gonadotropin and unconjugated estriol levels due to multifetal pregnancy reduction.

Conclusions:

• First-trimester multifetal reduction does not alter second-trimester levels of human chorionic gonadotropin and unconjugated estriol.
• Further research is necessary to validate screening analyte use for fetal chromosome abnormalities post-multifetal pregnancy reduction.
• Elevated alpha-fetoprotein warrants careful interpretation in pregnancies undergoing multifetal pregnancy reduction.